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Summary The activity of theophylline and disodium cromoglycate was tested on adriamycin-induced
histamine release in vitro and on adriamycin cardiotoxicity in vivo. Both substances significantly inhibited the
release of histamine induced by 100pgml-' of adriamycin on rat peritoneal cells and produced significant
protection against adriamycin-mediated acute and chronic cardiotoxicity in mice. N-acetylcysteine, a free
radical scavenger, successfully used in the prevention of the cardiomyopathy, was also found to be an
inhibitor of histamine release induced by adriamycin and compound 48/80 on rat peritoneal cells.
This study further supports the hypothesis that the release of histamine may be involved in the pathogenesis
of anthracycline cardiotoxicity.
Dose related cardiomyopathy eppears to be unique
to the anthracycline antibiotics (Unverferth et al.,
1982). Recent observations indicate that release of
histamine and other vasoactive substances may be
crucial in producing acute, subacute and chronic
cardiotoxicity. In particular, adriamycin induces
acute cardiovascular effects in dogs, that appear to
be related to the release of histamine and catechola-
mines and to increased prostaglandin synthesis
(Bristow et al., 1980). There is evidence also that
subacute cardiac damage in rabbits may be related
to the release of vasoactive substances and pretreat-
ment of animals with cromolyn produced signifi-
cant protection against this type of cardiomyopathy
(Bristow et al., 1983). Chronic cardiac effects may
also be related to histamine and catecholamine
release, as, in rabbits, pretreatment with antihista-
mines and antiadrenergics prevents the majority of
cardiac tissue damage (Bristow et al., 1981).
Adriamycin induces peritoneal mast cell
degranulation when injected intraperitoneally in
mice (Decorti et al., 1986a); in addition, this
substance and other anthracyclines cause a signifi-
cant and dose dependent histamine release from rat
peritoneal cells in vitro in a non cytotoxic manner
(Decorti et al., 1986b).
The present study was undertaken with the aim
of examining the effects of pretreatment with two
substances able to interfere with histamine release,
on the exocytotic response to adriamycin in vitro as
well as on adriamycin-induced cardiomyopathy in
vivo.
Materials and methods
In vitro studies
Mixed peritoneal cells were obtained from 200-
400 g male Sprague Dawley rats (Charles River,
Italy) by lavage of the peritoneal cavities with
saline solution at 37°C. The physiological solution
had the following composition: 1.54 x 101 M
NaCl, 2.7 x 10-3M KC1, 9 x10-4 M CaCl2,
5.6 x O-3 M D-glucose, human serum albumin
lgl-l and 10% by volume of a S6rensen buffer
containing 3 x 10-2 M Na2HPO4 x7H2O and
3.5 x10-2 M NaH2PO4xH2O. The pH of the
solution was adjusted to 7.2.
The cells were sedimented by centrifugation at
200-250g for 10min, the supernatant fraction was
removed and cells were resuspended in buffered
medium at a concentration of 180,000-
200,000ml-1. A pooled suspension from more rats
was employed for a day's experiment. The cell
suspension contained - 10% mast cells and was
used without further purification because only the
mast cells in such a suspension contain histamine
(Lagunoff et al., 1983).
In preliminary experiments adriamycin-induced
histamine release was also tested on purified
peritoneal mast cells.
Four hundred p1 aliquots of cells were pre-
incubated at 37°C in a metabolic shaker with gentle
mechanical agitation with various concentrations of
the inhibitors (200 p1 of a doubly concentrated
solution of the inhibitor in physiological saline were
added to 200 1 of the cell suspension). Cells were
pretreated with theophylline (10, 5, 2.5, 1.25, 0.62,
0.31, 0.15, 0.07mM) for 15min before stimulation;
disodium cromoglycate (10, 5, 2.5, 1.25, 0.62, 0.31,
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0.15, 0.07mM), n-acetylcysteine (200, 100, 50, 10, 1,
0.1 mM) and reduced glutathione (200, 100, 50, 10,
1, 0.1 mM) were added to the cells simultaneously
with the releasing agents. When n-acetylcysteine
was used, the solution was neutralized by the
addition of a small volume of sodium hydroxide
solution (5M). A solution (10lpu) of the releasing
agents (final concentration: adriamycin 100pgml-l
and compound 48/80 0.25pgml-1) was then added
and the incubation continued for a further 15min.
Samples were incubated in quadruplicate for
stated experimental times. Cells were separated
from supernatants by centrifugation at -200g for
3min. The cell pellets were suspended in 400dp
saline solution and allowed to stand in a boiling
water bath for 10min to release residual histamine;
the supernatants of controls were processed
similarly. All the samples were assayed for
histamine by the fluorimetric method of Shore et al.
(1959), omitting the extraction step. The amount of
histamine released was calculated as a percentage of
the total histamine present in the control
suspensions. All values were corrected for the
spontaneous release (- 5%) occurring in the
absence of the inducers.
In vivo studies
CD1 male mice (Charles River, Italy) of average
wt28-30g, were used. Animals were divided into 9
groups of 20 animals each: group 1 received adria-
mycin alone 15mgkg- 1 i.p.; group 2 received
adriamycin as in group 1 plus theophylline
100mgkg-1 i.p. 30min prior to adriamycin; group
3 received adriamycin as in group 1 plus disodium
cromoglycate 200mgkg-1 i.p. immediately before
adriamycin; group 4 received adriamycin 5mgkg-1
on days 1, 8 and 15 i.p.; group 5 received
adriamycin as in group 4 plus theophylline
100mgkg-1 i.p. 30min prior to each adriamycin
injection; group 6 received adriamycin as in group 4
plus disodium cromoglycate 200mgkg-1 i.p.
immediately prior to each adriamycin injection.
Additional groups of 10 animals received
theophylline (group 7) or cromolyn (group 8) i.p.
on days 1, 8 and 15 without following adriamycin
treatment; group 9 received i.p. injections of normal
saline and served as controls. Animals were
weighed weekly and inspected daily for survival and
general toxicity.
Five additional animals per group were sacrificed
by cervical dislocation after 7 (groups 1-3) or 30
(groups 4-9) days. An autopsy was performed and
specimens of the heart were collected and fixed in
3% glutaraldehyde in 0.1 M phosphate buffer at pH
7.4 and embedded in Epon 812. Sections were cut
at 1Mm, stained with 1% toluidine blue and
observed by light microscopy. Material so prepared
was scored on a coded 'blind' basis by two of us
(VG and FM).
Chemicals
Adriamycin was obtained from Farmitalia Carlo
Erba, Milan. Compound 48/80, theophylline,
disodium cromoglycate, n-acetylcysteine, reduced
glutathione, histamine dihydrochloride and o-
phthaldialdehydge were purchased from Sigma
Chemical Co., St. Louis, MO. All other chemicals
were of analytical grade.
Results
In vitro studies
Figure 1 shows that adriamycin (100pgml-1)
induces a significant histamine release from rat
peritoneal mast cells. This concentration was used
because it produced the most significant histamine
release without disruption of cells. No difference in
histamine release was observed when adriamycin
was tested on purified mast cells (data not shown).
Histamine release was significantly inhibited by
various doses of theophylline and cromolyn (Figure
1), by high concentrations of n-acetylcysteine, but
not of reduced glutathione. High concentrations of
n-acetylcysteine were also efficacious in inhibiting
histamine release induced by compound 48/80
(0.25pgml-1) (Figure 2).
In vivo studies
Adriamycin, when administered i.p. in an acute
(15mgkg-1) or chronic (5mgkg-1 week 1x
3weeks) regimen to CD1 mice, caused a severe drop
in body wt and a high mortality rate. Pretreatment
with theophylline and cromolyn prevented the
decrease in body wt and significantly improved the
survival time of the animals so treated (Figures 3
and 4). The doses of the antagonists chosen were
the highest ones devoid of toxicity.
The adriamycin-induced cardiac lesions observed
in this study were similar to those previously
described in other animal studies (Figures 5 and 6).
These lesions were virtually absent in mice pre-
treated with theophylline or cromolyn (Figures 7
and 8).
Discussion
The present study shows that substances able to
inhibit adriamycin-induced histamine release from
rat peritoneal mast cells in vitro, significantly
ameliorate the survival time and the microscopicHISTAMINE RELEASE MEDIATES ADRIAMYCIN CARDIOTOXICITY 745
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Figure 1 Effect of various concentrations of theophylline (T) and disodium cromoglicate (D) on histamine
release induced by 100pgml-1 of adriamycin (A). Columns are the means of 4 experiments and vertical bars
are s.e. Significantly different from adriamycin alone, Student's t test for independent samples (**: P<0.01,
***: P<0.001).
appearance of myocardial tissue of animals acutely
or chronically treated with adriamycin.
In previous studied we have shown that
adriamycin and other anthracyclines are able to
elicit a true exocytotic response from rat peritoneal
mast cells; this release is very similar in its bio-
chemical features to that induced by compound
48/80, but contrasts with that induced by antigens
(Decorti et al., 1986a, b). In studies performed by
other authors (Riegel et al., 1982), on the contrary,
adriamycin did not produce significant histamine
release on purified or unpurified rat mast cells in
vitro, but caused a dose-related histamine release in
vivo after i.p. injection. It should however be noted
that in in vitro experiments performed in this paper,
histamine was not directly measured, but the
amount of serotonin released was calculated,
assuming that the two substances behave
identically.
Two substances known to inhibit 48/80-induced
histamine release from rat peritoneal mast cells,
theophylline (Loeffler et al., 1971) and disodium
cromoglycate (Orr et al., 1971) have proved able to
limit the release induced by adriamycin as well.
These data together with the observations that
theophylline and cromolyn are effective in amelior-
ating adriamycin-induced cardiotoxicity confirm the
observations of other researchers (Bristow et al.,
1980, 1981, 1983) indicating a major role for
histamine in inducing adriamycin cardiotoxicity.
Among the various other pathogenetic
hypotheses for adriamycin-induced cardio-
myopathy, the generation of drug-induced reactive
oxygen radicals in heart cells, leading to cardiac
lipid membrane peroxidation, has been frequently
advocated (Bachur et al., 1978; Myers et al., 1977);
hence various agents acting' as free radical
scavengers have been employed in the effort to
prevent this side effect. N-acetylcysteine, in
particular, significantly decreased lethality and
ablated microscopic evidence of adriamycin cardio-
myopathy in various experimental models
(Doroshow et al., 1981; Kimball et al., 1979). It is
noteworthy that, in our in vitro system, N-acetyl-
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Figure 2 Effect of various concentrations of n-acetylcysteine (N) and reduced glutathione (G) on the release
of histamine induced by 100l ugml-m of adriamycin (A) or 0.25 ugml-P of compound 48/80 (C). Columns are
the means of 4 experiments and vertical bars show s.e. Significantly different from the releasing agents alone,
Student's t test for independent samples (*: P<0.05, **: P<0.01, ***: P<0.001).
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Figure 3 Cumulative mortality data for mice Figure 4 Cumulative mortality data for mice
receiving (A) adriamycin 15mgkg-1, (0) adriamycin receiving (A) adriamycin 5mgkg -week- 1 x 3weeks,
15mgkg-1 plus disodium cromoglycate 200mgkg-1, (0) adriamycin 5mgkg- week- 1 x 3 weeks plus
(-) adriamycin 15mgkg-1 plus theophylline disodium cromoglycate 200mgkg- week-1 x 3 weeks,
100mg kg - and (L1) controls (disodium cromoglycate (U) adriamycin 5mgkg- week-I x 3 weeks plus
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Figure 5 Severe damage with myocytic vacuolization in the ventricular tissue of a mouse receiving
adriamycin 5mgkg-1 week- 1 x 3weeks i.p. ( x 800).
Figure 6 Myofibrillar loss and microhaemorrhages in the ventricular tissue of a mouse receiving adriamycin
5mgkg-1 week -1 x 3weeks i.p. ( x 800).
Figure 7 Light microscopic appearance of the ventricular tissue of a mouse receiving adriamycin
5mgkg- 1 week- I x 3weeks i.p. plus theophylline l00mgkg-1 week -1 x 3weeks i.p. ( x 800).
Figure 8 Light microscopic appearance of the ventricular tissue of a mouse receiving adriamycin
5mgkg-1 week-1 x 3weeks i.p. plus disodium cromoglycate 200mgkg-1 week - I x 3weeks i.p. ( x 800).
cysteine inhibited adriamycin as well as compound
48/80-induced histamine release, even if at very
high doses. Among the several mechanisms
initiating mast cell secretion and noncytotoxic
release of histamine, are also oxidative metabolites
like H202 (Ohmori et al., 1979); however we
suggest that the mechanism of action of N-acetyl-
cysteine is probably different from the free radical
scavanging activity, as in our experimental system,
it significantly limited also the release induced by
compound 48/80. In addition, reduced glutathione,
a free radical scavanger able to reduce the release
of histamine induced by paracetamol (Brunelleschi
et al., 1985), was ineffective in limiting the mast cell
secretion induced by adriamycin and compound
48/80.
Our results indicating that substances able to
inhibit histamine release in vitro can also prevent
adriamycin cardiac toxicity in vivo, further support
the hypothesis that histamine may play a role in the
development of adriamycin cardiomyopathy. Hence
the use of substances able to interfere with
histamine release may provide a means to reduce
the toxicity of this antineoplastic drug.
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